Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

79 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Validation and limitations of use of a breast cancer nomogram predicting the likelihood of non-sentinel node involvement after positive sentinel node biopsy.
Alran S, De Rycke Y, Fourchotte V, Charitansky H, Laki F, Falcou MC, Benamor M, Freneaux P, Salmon RJ; Institut Curie Breast Cancer Study Group; Sigal-Zafrani B. Alran S, et al. Among authors: fourchotte v. Ann Surg Oncol. 2007 Aug;14(8):2195-201. doi: 10.1245/s10434-006-9331-2. Epub 2007 Feb 9. Ann Surg Oncol. 2007. PMID: 17294071
The molecular subtype classification is a determinant of sentinel node positivity in early breast carcinoma.
Reyal F, Rouzier R, Depont-Hazelzet B, Bollet MA, Pierga JY, Alran S, Salmon RJ, Fourchotte V, Vincent-Salomon A, Sastre-Garau X, Antoine M, Uzan S, Sigal-Zafrani B, De Rycke Y. Reyal F, et al. Among authors: fourchotte v. PLoS One. 2011;6(5):e20297. doi: 10.1371/journal.pone.0020297. Epub 2011 May 31. PLoS One. 2011. PMID: 21655258 Free PMC article.
Non-sentinel lymph node metastasis prediction in breast cancer with metastatic sentinel lymph node: impact of molecular subtypes classification.
Reyal F, Belichard C, Rouzier R, de Gournay E, Senechal C, Bidard FC, Pierga JY, Cottu P, Lerebours F, Kirova Y, Feron JG, Fourchotte V, Vincent-Salomon A, Guinebretiere JM, Sigal-Zafrani B, Sastre-Garau X, De Rycke Y, Coutant C. Reyal F, et al. Among authors: fourchotte v. PLoS One. 2012;7(10):e47390. doi: 10.1371/journal.pone.0047390. Epub 2012 Oct 9. PLoS One. 2012. PMID: 23056641 Free PMC article.
Efficacy and safety of bevacizumab-containing neoadjuvant therapy followed by interval debulking surgery in advanced ovarian cancer: Results from the ANTHALYA trial.
Rouzier R, Gouy S, Selle F, Lambaudie E, Floquet A, Fourchotte V, Pomel C, Colombo PE, Kalbacher E, Martin-Francoise S, Fauvet R, Follana P, Lesoin A, Lecuru F, Ghazi Y, Dupin J, Chereau E, Zohar S, Cottu P, Joly F. Rouzier R, et al. Among authors: fourchotte v. Eur J Cancer. 2017 Jan;70:133-142. doi: 10.1016/j.ejca.2016.09.036. Epub 2016 Dec 1. Eur J Cancer. 2017. PMID: 27914243 Free article. Clinical Trial.
Clinical and genetic landscape of treatment naive cervical cancer: Alterations in PIK3CA and in epigenetic modulators associated with sub-optimal outcome.
Scholl S, Popovic M, de la Rochefordiere A, Girard E, Dureau S, Mandic A, Koprivsek K, Samet N, Craina M, Margan M, Samuels S, Zijlmans H, Kenter G, Hillemanns P, Dema S, Dema A, Malenkovic G, Djuran B, Floquet A, Garbay D, Guyon F, Colombo PE, Fabbro M, Kerr C, Ngo C, Lecuru F, Campo ERD, Coutant C, Marchal F, Mesgouez-Nebout N, Fourchotte V, Feron JG, Morice P, Deutsch E, Wimberger P, Classe JM, Gleeson N, von der Leyen H, Minsat M, Dubot C, Gestraud P, Kereszt A, Nagy I, Balint B, Berns E, Jordanova E, Saint-Jorre N, Savignoni A, Servant N, Hupe P, de Koning L, Fumoleau P, Rouzier R, Kamal M. Scholl S, et al. Among authors: fourchotte v. EBioMedicine. 2019 May;43:253-260. doi: 10.1016/j.ebiom.2019.03.069. Epub 2019 Apr 2. EBioMedicine. 2019. PMID: 30952619 Free PMC article.
79 results